\
&
Contact us
\
&
Contact us
Published on | 4 years ago
Programmes Health Culture and society Horizon EuropeCoronavirus Global R&I Collaboration Portal launched by European Commission
On the first day of the 2021 edition of the European Research and Innovation Days, the European Commission launched a new online matchmaking and networking platform to facilitate cross-border collaboration between researchers and research projects with a focus on the socio-economic aspects of the coronavirus pandemic. On the platform you can explore different types of collaboration opportunities, from co-authorship and peer reviews to requests for joint funding applications. You can also browse member profiles and get in touch with them and showcase your ongoing research related to the topic. The Coronavirus Global R&I Collaboration Portal is now open for registrations. You can create your member profile here.
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
